Located just around the corner from us in Durham, NC, Chimerix is developing a pipeline of therapeutics that address life-threatening viral diseases. The company derives its product candidates from Phospholipid Intramembrane Microfluidization Conjugate Technology, which can enhance the activity, bioavailability and safety of useful drugs. This technology has given rise to two clinical-stage compounds that have demonstrated the potential for enhanced antiviral activity and safety. Chimerix’s lead compound, brincidofovir (BCV), is a broad-spectrum oral antiviral agent that is initially being developed for the treatment of CMV and AdV in transplant patients.
Chimerix raised over $100 million in its initial public offering in April 2013.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.